Ferring Advances Three Studies in ADSTILADRIN® (nadofaragene firadenovec-vncg) Clinical Trial Program
Ferring activates first sites in a three-arm study of ADSTILADRIN as a monotherapy or in combination with chemotherapy or an ...
Intravesical gemcitabine/docetaxel as an alternative therapy for patients with non-muscle-invasive bladder cancer
The treatment guidelines for non-muscle-invasive bladder cancer (NMIBC) consist of endoscopic resection of the tumor, then ...
Targeted Oncology12d
FGFR-Altered NMIBC Treatment Advances With TAR-210 Findings
In an interview, Antoni Vilaseca Cabo, MD, discussed the clinical activity of TAR-210 in patients with non-muscle invasive ...
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
Details on the late-breaking abstract and posters are as follows: Topline Results from BOND-003: A Phase-3 Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High-Risk ...
Nature15y
Intravesical MCC for bladder cancer
Mycobacterial cell wall–DNA complex (MCC) is an effective treatment modality for bladder cancer, and has a favorable safety profile when compared with intravesical therapy using live bacillus ...
Nature5y
Adjuvant, intravesical BCG therapy is cost-effective
Adjuvant, intravesical bacillus Calmette–Guérin (BCG) therapy reduces the risk of recurrence and progression of superficial bladder cancer, but confers a considerable risk of local and systemic ...